S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
CGC   15.83 (-14.43%)
BABA   182.68 (+0.11%)
GE   11.29 (+0.00%)
T   38.96 (-0.51%)
F   8.81 (+0.00%)
BAC   32.75 (-0.12%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
CGC   15.83 (-14.43%)
BABA   182.68 (+0.11%)
GE   11.29 (+0.00%)
T   38.96 (-0.51%)
F   8.81 (+0.00%)
BAC   32.75 (-0.12%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
CGC   15.83 (-14.43%)
BABA   182.68 (+0.11%)
GE   11.29 (+0.00%)
T   38.96 (-0.51%)
F   8.81 (+0.00%)
BAC   32.75 (-0.12%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
CGC   15.83 (-14.43%)
BABA   182.68 (+0.11%)
GE   11.29 (+0.00%)
T   38.96 (-0.51%)
F   8.81 (+0.00%)
BAC   32.75 (-0.12%)
Log in

Bio-Rad Laboratories Stock Price, Forecast & Analysis (NYSE:BIO)

$354.58
+2.66 (+0.76 %)
(As of 11/14/2019 04:00 PM ET)
Today's Range
$349.63
Now: $354.58
$355.21
50-Day Range
$320.26
MA: $340.91
$355.67
52-Week Range
$220.05
Now: $354.58
$358.89
Volume3,945 shs
Average Volume217,849 shs
Market Capitalization$10.61 billion
P/E Ratio60.72
Dividend YieldN/A
Beta1.16
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.29 billion
Cash Flow$6.01 per share
Book Value$171.42 per share

Profitability

Net Income$365.61 million

Miscellaneous

Employees8,260
Market Cap$10.61 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.


Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories' stock buyback program work?

Bio-Rad Laboratories declared that its board has authorized a share buyback program on Wednesday, November 29th 2017, which authorizes the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its quarterly earnings results on Thursday, October, 31st. The medical research company reported $1.61 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.36 by $0.25. The medical research company earned $560.60 million during the quarter, compared to analyst estimates of $561.40 million. Bio-Rad Laboratories had a net margin of 16.14% and a return on equity of 4.30%. The company's revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.91 earnings per share. View Bio-Rad Laboratories' Earnings History.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Bio-Rad Laboratories.

What price target have analysts set for BIO?

3 equities research analysts have issued 1 year price targets for Bio-Rad Laboratories' stock. Their forecasts range from $375.00 to $400.00. On average, they anticipate Bio-Rad Laboratories' share price to reach $385.00 in the next twelve months. This suggests a possible upside of 8.6% from the stock's current price. View Analyst Price Targets for Bio-Rad Laboratories.

What is the consensus analysts' recommendation for Bio-Rad Laboratories?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Rad Laboratories.

Has Bio-Rad Laboratories been receiving favorable news coverage?

Media coverage about BIO stock has trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bio-Rad Laboratories earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Bio-Rad Laboratories.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 408,100 shares, an increase of 12.8% from the September 30th total of 361,800 shares. Based on an average daily volume of 220,700 shares, the days-to-cover ratio is presently 1.8 days. Approximately 1.9% of the company's stock are short sold. View Bio-Rad Laboratories' Current Options Chain.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), First Solar (FSLR), Dynavax Technologies (DVAX), ImmunoGen (IMGN), Celgene (CELG), Exelixis (EXEL) and Array Biopharma (ARRY).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
  • Ms. Christine A. Tsingos, Exec. Officer (Age 60)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 64)

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.84%), Russell Investments Group Ltd. (0.75%), Intermede Investment Partners Ltd (0.65%), Tamarack Advisers LP (0.39%), GW&K Investment Management LLC (0.33%) and Artemis Investment Management LLP (0.31%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, Giovanni Magni, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Institutional Ownership Trends for Bio-Rad Laboratories.

Which major investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Sector Gamma AS, First Trust Advisors LP, Roubaix Capital LLC, Eagle Asset Management Inc., Synovus Financial Corp, Gamco Investors INC. ET AL and First Citizens Bank & Trust Co.. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Christine A Tsingos, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Insider Buying and Selling for Bio-Rad Laboratories.

Which major investors are buying Bio-Rad Laboratories stock?

BIO stock was bought by a variety of institutional investors in the last quarter, including Intermede Investment Partners Ltd, Artemis Investment Management LLP, Columbus Circle Investors, Tamarack Advisers LP, California Public Employees Retirement System, Fisher Asset Management LLC, GW&K Investment Management LLC and Sciencast Management LP. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $354.58.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $10.61 billion and generates $2.29 billion in revenue each year. The medical research company earns $365.61 million in net income (profit) each year or $5.84 on an earnings per share basis. Bio-Rad Laboratories employs 8,260 workers across the globe.View Additional Information About Bio-Rad Laboratories.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is http://www.bio-rad.com/.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  311 (Thanks for Voting!)
Underperform Votes:  320 (Thanks for Voting!)
Total Votes:  631
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel